Slidesets V-FAST Subgroup Analysis: CPX-351 + Midostaurin in Newly Diagnosed AML by FLT3 Mutation Slidesets GRAALL-2014/B Quest Cohort Analysis: Blinatumomab During Consolidation in Adults With High-Risk Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia Slidesets GMALL-INITIAL1: Inotuzumab Ozogamicin Induction Therapy Followed by Standard Chemotherapy in Older Patients With B-Lymphoblastic Leukemia Slidesets VIALE-A: Extended Follow-up of Azacitidine ± Venetoclax in Patients With Treatment-Naive AML Ineligible for Standard Induction Chemotherapy Slidesets Phase I/II Trial of Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML Slidesets Low-Dose Dasatinib for Newly Diagnosed CML: Long-term Follow-up Outcomes Slidesets AUGMENT-101: Phase I Study of Revumenib in Patients With KMT2A-Rearranged or NPM1-Mutant AML Slidesets Phase I/II KOMET-001: First-in-Human Study of Ziftomenib, a Novel KMT2A-Menin Inhibitor, in Relapsed/Refractory AML Slidesets ASC4MORE: Phase II Trial of Addition of Asciminib to Imatinib vs Continued Imatinib vs Switch to Nilotinib in Patients With Chronic-Phase CML Not Achieving Deep Molecular Responses With ≥1 Yr of Imatinib Therapy Slidesets Phase I/II Trial of Triplet Combination of Gilteritinib + Azacitidine/Venetoclax in Patients With FLT3-Mutated AML: Updated Results Slidesets ECOG-ACRIN E1910: Phase III Study of Consolidation Chemotherapy ± Blinatumomab in MRD-Negative BCR::ABL1-Negative B-ALL